| Literature DB >> 32922877 |
Chongshun Zhao1, Zhouqing Chen1, Na Xu2, Tao Xue1, Xin Wu1, Wanchun You1, Yun Zhu1, Zhong Wang1.
Abstract
BACKGROUND: Craniopharyngioma is a kind of intracranial benign tumor that is primarily treated with surgery. At present, a variety of surgical approaches are used for tumor resection. We have conducted a comparative analysis of the two approaches most used in our department.Entities:
Keywords: Craniopharyngioma; Lateral supraorbital approach; Standard pterional approach
Year: 2018 PMID: 32922877 PMCID: PMC7398233 DOI: 10.1186/s41016-018-0126-7
Source DB: PubMed Journal: Chin Neurosurg J ISSN: 2057-4967
Comparison of preoperative conditions between two groups of patients
| Variables | LSO approach group | Standard pterional approach group | |
|---|---|---|---|
| Classification | 0.944 | ||
| Intrasellar | 0 | 1 | |
| Intra-suprasellar | 8 | 13 | |
| Intra-suprasellar-intraventricular | 5 | 10 | |
| Suprasellar-extraventricular | 5 | 8 | |
| Suprasellar-intraventricular | 6 | 9 | |
| Intraventricular | 0 | 0 | |
| Tumor size (cm) | 3.6 ± 1.39 | 3.3 ± 1.09 | 0.228 |
| Sex | 0.519 | ||
| Female | 10 | 16 | |
| Male | 14 | 25 | |
| Age (year) | 52.0 ± 19.67 | 46.6 ± 16.19 | 0.234 |
| Pre-operation endocrine disorders | |||
| Triiodothyronine | 13 | 14 | 0.128 |
| Thyrine | 10 | 13 | 0.435 |
| HormotHyrin | 3 | 4 | 0.703 |
| Hudrocortisone | 11 | 22 | 0.612 |
| Flitropin | 8 | 15 | 1.000 |
| Prolan B | 13 | 23 | 1.000 |
| Prolactin | 17 | 26 | 0.597 |
| Growth hormone | 0 | 1 | 1.000 |
Tumor size and classification distribution.
| Classification | Tumor size | ||||
|---|---|---|---|---|---|
| Small | Medium | Large | Huge | Total | |
| Intrasellar | 1 | 0 | 0 | 0 | 1 |
| Intra-suprasellar | 1 | 18 | 2 | 0 | 21 |
| Intra-suprasellar-intraventricular | 1 | 8 | 4 | 2 | 15 |
| Suprasellar-extraventricular | 2 | 11 | 0 | 0 | 13 |
| Suprasellar-intraventricular | 0 | 10 | 5 | 0 | 15 |
| Intraventricular | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 47 | 11 | 2 | 65 |
Fig. 1Three common craniopharyngioma MRI’s sagittal and two gaps of tumor exposure under the supraorbital visual field. a intra-suprasellar, b suprasellar-extrayentricular, c intra-suprasellar-intraventricular, d expose tumor from the first gap, e expose tumor from the second gap
Surgical results
| LSO approach | Standard pterional approach | ||
|---|---|---|---|
| Operation time (Min) | 205.4 ± 65.71 | 289.9 ± 89.89 | 0.001 |
| Incision length (Cm) | 8.21 ± 1.91 | 15.07 ± 3.47 | 0.001 |
| Tumor resection | 0.545 | ||
| complete resection | 20(83.3%) | 35(85.4%) | |
| partial resection | 4(16.7%) | 6(14.6%) | |
| Hospitalization days (Day) | 22.25 ± 7.89 | 24.80 ± 11.68 | 0.258 |
| Postoperative hospital days (Day) | 16.41 ± 7.42 | 18.66 ± 11.67 | 0.220 |
Fig. 2Contrast LSO approach and Standard pterional approach postoperative hormone secretion dysfunction. The LSO is represented by blue column and the standard pterional approach is represented by red column
Fig. 3Contrast LSO approach and Standard pterional approach average daily urine volume within a week after surgery. The LSO is represented by a blue line, and the standard pterion path is indicated by a red line